Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 41

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 41
---
 The Series E Warrants and December 2023 Underwriter Warrants expire five years and three
years, respectively from the initial exercise date. The December 2023 Private Placement Pre-Funded Warrants are exercisable at any time
and do not expire. The holder shall deliver the aggregate exercise price for the Depositary Shares specified in the exercise notice within
two trading days following the date of exercise (subject to the ‘cashless exercise’ arrangements described below).

| 28 |

Cashless Exercise. If, at the time a holder exercises its Series E Warrants, a registration statement registering the issuance of
the securities underlying the Series E Warrants under the Securities Act is not then effective or available and an exemption from
registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise
contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon
such exercise (either in whole or in part) the net number of Depositary Shares determined according to a formula set forth in the Series E
Warrants.

At the time a holder exercises
its December 2023 Private Placement Pre-Funded Warrants, in lieu of making the cash payment otherwise contemplated to be made to us upon
such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole
or in part) the net number of Depositary Shares determined according to a formula set forth in the December 2023 Private Placement Pre-Funded
Warrants.

Exercise Price.The
exercise price of each Series E Warrant, December 2023 Underwriter Warrant and December 2023 Private Placement Pre-Funded Warrant is $55.00,
$62.50 and $0.0025 per Depositary Share.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect
to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder
or any such affiliate, would beneficially own in excess of 9.99% (or in the case of the December 2023Underwriter Warrants, 4.99%), of the number of Ordinary Shares outstanding immediately after giving effect to the issuance
of the Ordinary Shares underlying the Depositary Shares upon such exercise. The holder of the warrant, upon notice to us,